Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311597 | 1.00 | F10 (0.46) | F10F2LNPEPCTSGCTRB1 | |
| SCHEMBL2315825 | 0.86 | NLRP3 (0.43) | LNPEPSMN1; SMN2MEN1KMT2ARAB9A | |
| SCHEMBL2318044 | 0.83 | MAPT (0.47) | F10CTSGCTRB1SMN1; SMN2POLB | |
| SCHEMBL2318048 | 0.83 | MAPT (0.47) | F10CTSGCTRB1SMN1; SMN2POLB | |
| SCHEMBL19157175 | 0.78 | NLRP3 (0.46) | SMN1; SMN2MEN1KMT2ARAB9ANLRP3 | |
| SCHEMBL2312151 | 0.77 | ALDH1A1 (0.42) | F2SMN1; SMN2POLBNLRP3HDAC6 | |
| SCHEMBL2312159 | 0.77 | ALDH1A1 (0.42) | F2SMN1; SMN2POLBNLRP3HDAC6 | |
| SCHEMBL2311407 | 0.72 | F2 (0.55) | F10F2SMN1; SMN2PRSS1MEN1 | |
| SCHEMBL8903673 | 0.72 | F2 (0.55) | F10F2SMN1; SMN2PRSS1MEN1 | |
| SCHEMBL18065683 | 0.71 | F2 (0.54) | F10F2SMN1; SMN2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2152674-B1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-2152674-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147697-A1 | BENZIMIDAZOLONE CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | F10 2429/4885F2 3847/4885LNPEP 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.